This post was written by Eugene Rubin, MD, Ph.D., and Charles Zorumski, MD. Schizophrenia is a severe, chronic disorder characterized by "positive" symptoms such as hallucinations, delusions (fixed, ...
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which ...
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking ...
ENIGMA-TRS 1 is an international, one-year, double-blind, placebo-controlled Phase III study in at least 600 patients; enrollment to start imminently; 12-week study results expected in Q4 2026 ...
New post-hoc analyses highlighting the clinical benefit of evenamide for patients with treatment-resistant schizophrenia (TRS ...
Philip Cola, professor of design and innovation at Weatherhead School of Management, recently penned an article published in the Journal of Clinical Psychopharmacology. Cola also holds a secondary ...
Consistent with short-term studies, KarXT was not associated with clinically meaningful changes in movement disorder scale scores and a low incidence rate of extrapyramidal symptoms was reported over ...
Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback